



Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: AMRN

| | |
|---------------|-----------------------------|
| Last Trade: | 4.29 |
| Trade Time: | 10:33 AM ET Jan 16, 2018 |
| Change: | 0.04 (+0.941%) |
| Day Range | 4.26 - 4.32 |
| 52-Week Range | 2.81 - 4.47 |
| Volume | 262,273 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 4, 2018*
[Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook](#)
- Dec 19, 2017*
[Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018](#)
- Dec 18, 2017*
[Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco](#)
- Nov 14, 2017*
[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)
- Nov 13, 2017*
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)